| 產(chǎn)品名稱 | 
      Mycobacterium neworleansense Schinsky et al. | 
    
    
      | 商品貨號 | 
      B162248 | 
    
      
      | Deposited As | 
      Mycobacterium fortuitum da Costa Cruz | 
    
      
      | Strain Designations | 
      Mf 465 [W6705, DSM 44679, JCM 15659] | 
    
      
      | Isolation | 
      Tissue, human scalp wound infection, New Orleans, LA, USA, By RJ Wallace, 1987  | 
    
      
      | Biosafety Level | 
      2 
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.   | 
    
      
      | Product Format | 
      freeze-dried | 
    
      
      | Storage Conditions | 
      Frozen: -80°C or colder Freeze-Dried: 2°C to 8°C Live Culture: See Propagation Section | 
    
      
      | Preceptrol® | 
      no | 
    
      
      | Type Strain | 
      yes
                                                
                                            Ref  Schinsky MF, et al. Taxonomic variation in the Mycobacterium fortuitum third biovariant complex: description of Mycobacterium boenickei sp. nov., Mycobacterium houstonense sp. nov., Mycobacterium neworleansense sp. nov. and Mycobacterium brisbanense sp. nov. and recognition of Mycobacterium porcinum from human clinical isolates..  Int. J. Syst. Evol. Microbiol. 54: 1653-1667, 2004. PubMed: 15388725 | 
    
      
      | Comments | 
      Biovariant 3  | 
    
      
      | Medium | 
      ATCC® Medium 44: Brain Heart Infusion Agar/Broth
  | 
    
      
      | Growth Conditions | 
      Temperature: 37°C 
Atmosphere: Aerobic  | 
    
      
      | Name of Depositor | 
      RJ Wallace | 
    
      
      | Chain of Custody | 
      ATCC <-- RJ Wallace <-- G. Bedsole <-- Charity Hosp., New Orleans, LA  | 
    
      
      | References | 
      
            Silcox VA, et al.  Identification of clinically significant Mycobacterium fortuitum complex isolates.  J. Clin. Microbiol. 14(6): 686-691, 1981.  PubMed: 7037841
         
    
        
            Wallace RJ J, et al. Clinical disease, drug susceptibility, and biochemical patterns of the unnamed third biovariant complex of Mycobacterium fortuitum.  J. Infect. Dis. 163: 598-603, 1991. PubMed: 1995732
         
    
        
            Schinsky MF, et al. Taxonomic variation in the Mycobacterium fortuitum third biovariant complex: description of Mycobacterium boenickei sp. nov., Mycobacterium houstonense sp. nov., Mycobacterium neworleansense sp. nov. and Mycobacterium brisbanense sp. nov. and recognition of Mycobacterium porcinum from human clinical isolates..  Int. J. Syst. Evol. Microbiol. 54: 1653-1667, 2004. PubMed: 15388725
         
    
        
            Schinsky MF, et al. Taxonomic variation in the Mycobacterium fortuitum third biovariant complex: description of Mycobacterium boenickei sp. nov., Mycobacterium houstonense sp. nov., Mycobacterium neworleansense sp. nov. and Mycobacterium brisbanense sp. nov. and recognition of Mycobacterium porcinum from human clinical isolates..  Int. J. Syst. Evol. Microbiol. 54: 1653-1667, 2004. PubMed: 15388725
          | 
    
      
      | Cross References | 
      
            Nucleotide (GenBank)  : 
            
                    X65529
                 
             M.fortuitum 16S rRNA (ATCC 49404)
         
    
        
            Nucleotide (GenBank)  : 
            
                    U86086
                 
             Mycobacterium fortuitum superoxide dismutase (SOD) gene, partial cds
         
    
        
            Nucleotide (GenBank)  : 
            
                    AY012575
                 
             Mycobacterium neworleansense strain W6705 16S ribosomal RNA gene, partial sequence
         
    
        
            Nucleotide (GenBank)  : 
            
                    AY457068
                 
             Mycobacterium fortuitum subsp. fortuitum strain ATCC 49404 16S ribosomal RNA gene, partial sequence
          |